{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "EMA EPAR|DISEASES|MUSCULOSKELETAL DISEASES|RHEUMATIC DISEASES" in comments (approximate match)
Status:
US Approved Rx
(2023)
Source:
ANDA205443
(2023)
Source URL:
First approved in 2009
Source:
NDA021856
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Febuxostat (ULORIC) is a novel, xanthine oxidase/dehydrogenase (XO/XDH) inhibitor being developed by Teijin, TAP Pharmaceuticals, and Ipsen for the treatment of gout. The currently available XO inhibitor, allopurinol, has been associated with serious instances of severe hypersensitivity, in some cases leading to fatalities. There is some suggestion that febuxostat is less prone to excacerbate systemic inflammatory events in animal studies. Febuxostat, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations. Febuxostat is used for the treatment of hyperuricemia in patients with gout.
Status:
US Approved Rx
(2010)
Source:
BLA125293
(2010)
Source URL:
First approved in 2010
Source:
BLA125293
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2013)
Source:
BLA125472
(2013)
Source URL:
First approved in 2010
Source:
BLA125276
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2009)
Source:
BLA125319
(2009)
Source URL:
First approved in 2009
Source:
BLA125319
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2013)
Source:
BLA125433
(2013)
Source URL:
First approved in 2009
Source:
BLA125289
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2008)
Source:
BLA125160
(2008)
Source URL:
First approved in 2008
Source:
BLA125160
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2005)
Source:
BLA125118
(2005)
Source URL:
First approved in 2005
Source:
BLA125118
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2021)
Source:
BLA761216
(2021)
Source URL:
First approved in 2002
Source:
BLA125057
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2001)
Source:
BLA103950
(2001)
Source URL:
First approved in 2001
Source:
BLA103950
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761086
(2019)
Source URL:
First approved in 1998
Source:
BLA103772
Source URL:
Class:
PROTEIN
